Cross-topic event
FDA Approves Pembrolizumab Plus Belzutifan for Adjuvant High-Risk Clear Cell Kidney Cancer
Jun 15, 20262 reports
Jun 15, 2026
Sciencedesk view
FDA Approves Pembrolizumab Plus Belzutifan for Adjuvant High-Risk Clear Cell Kidney Cancer
Per a Merck press release on June 12, 2026, the U.S. FDA approved KEYTRUDA (pembrolizumab) and subcutaneous KEYTRUDA QLEX, each combined with WELIREG (belzutifa…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
FDA Approves Pembrolizumab Plus Belzutifan for High-Risk Kidney Cancer After Surgery
Per MedicalXpress on June 15, the FDA approved pembrolizumab (anti–PD-1) plus belzutifan (HIF-2α inhibitor) as adjuvant therapy for adults with intermediate-hig…
READ THE DAY'S DIGEST →